Payment overview · 2025
General Payments
$1,047.96
32 reported records · 12 companies
Healthcare provider profile · identity verified
Amy Beckman, DO, MSMED
Allopathic & Osteopathic Physicians|Family Medicine · ERIE, PA · NPI 1780244111
Verified facts
What the public records show
CMS Open Payments records show Amy Beckman, DO, MSMED received $1,047.96 in general payments during 2025 across 32 reported records.
Exact Sciences Corporation accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $377.70 | 36.0% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $197.20 | 18.8% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $135.75 | 12.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.93 | 7.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.60 | 4.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $45.14 | 4.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.29 | 3.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.74 | 3.7% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $31.54 | 3.0% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $23.62 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.83 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.62 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,047.96 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $223.79 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $197.20 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $153.91 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $117.70 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $78.93 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.60 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.21 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.56 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 272 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 261 | 59 |
| Omeprazole | Omeprazole | 201 | 33 |
| Gabapentin | Gabapentin | 181 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 145 | 29 |
| Lisinopril | Lisinopril | 141 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 32 |
| Lorazepam | Lorazepam | 106 | 17 |
| Furosemide | Furosemide | 100 | 24 |
| Simvastatin | Simvastatin | 99 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 18 |
| Metformin Hcl | Metformin Hcl | 87 | 32 |
| Potassium Chloride | Potassium Chloride | 80 | 15 |
| Alprazolam | Alprazolam | 72 | 12 |
| Tramadol Hcl | Tramadol Hcl | 71 | 13 |
| Atenolol | Atenolol | 69 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 16 |
| Xarelto | Rivaroxaban | 63 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 62 | 14 |
| Famotidine | Famotidine | 61 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 18 |
| Meloxicam | Meloxicam | 56 | 15 |
| Celecoxib | Celecoxib | 47 | suppressed |
| Chlorthalidone | Chlorthalidone | 46 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 12 |
| Allopurinol | Allopurinol | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Losartan Potassium | Losartan Potassium | 38 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Ozempic | Semaglutide | 34 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 26 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Eliquis | Apixaban | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 13 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Eletriptan Hbr | Eletriptan Hydrobromide | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Rybelsus | Semaglutide | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,047.96 · 32 records | Exact Sciences Corporation | AIRSUPRA, AVVIGO Guidance System, BREZTRI, Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, OTEZLA, REPATHA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VIVITROL, WATCHMAN Access System, Wegovy, XIENCE SKYPOINT, XIFAXAN, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error